Systematic Review
. 2010 Nov; 47(1):8-32.
doi: 10.1016/j.ejca.2010.10.013.

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

M S Aapro 1 J Bohlius  D A Cameron  Lissandra Dal Lago  J Peter Donnelly  N Kearney  G H Lyman  R Pettengell  V C Tjan-Heijnen  J Walewski  Damien C Weber  C Zielinski  European Organisation for Research and Treatment of Cancer  
  • PMID: 21095116
  •     305 citations


Chemotherapy-induced neutropenia is a major risk factor for infection-related morbidity and mortality and also a significant dose-limiting toxicity in cancer treatment. Patients developing severe (grade 3/4) or febrile neutropenia (FN) during chemotherapy frequently receive dose reductions and/or delays to their chemotherapy. This may impact the success of treatment, particularly when treatment intent is either curative or to prolong survival. In Europe, prophylactic treatment with granulocyte-colony stimulating factors (G-CSFs), such as filgrastim (including approved biosimilars), lenograstim or pegfilgrastim is available to reduce the risk of chemotherapy-induced neutropenia. However, the use of G-CSF prophylactic treatment varies widely in clinical practice, both in the timing of therapy and in the patients to whom it is offered. The need for generally applicable, European-focused guidelines led to the formation of a European Guidelines Working Party by the European Organisation for Research and Treatment of Cancer (EORTC) and the publication in 2006 of guidelines for the use of G-CSF in adult cancer patients at risk of chemotherapy-induced FN. A new systematic literature review has been undertaken to ensure that recommendations are current and provide guidance on clinical practice in Europe. We recommend that patient-related adverse risk factors, such as elderly age (≥65 years) and neutrophil count be evaluated in the overall assessment of FN risk before administering each cycle of chemotherapy. It is important that after a previous episode of FN, patients receive prophylactic administration of G-CSF in subsequent cycles. We provide an expanded list of common chemotherapy regimens considered to have a high (≥20%) or intermediate (10-20%) risk of FN. Prophylactic G-CSF continues to be recommended in patients receiving a chemotherapy regimen with high risk of FN. When using a chemotherapy regimen associated with FN in 10-20% of patients, particular attention should be given to patient-related risk factors that may increase the overall risk of FN. In situations where dose-dense or dose-intense chemotherapy strategies have survival benefits, prophylactic G-CSF support is recommended. Similarly, if reductions in chemotherapy dose intensity or density are known to be associated with a poor prognosis, primary G-CSF prophylaxis may be used to maintain chemotherapy. Clinical evidence shows that filgrastim, lenograstim and pegfilgrastim have clinical efficacy and we recommend the use of any of these agents to prevent FN and FN-related complications where indicated. Filgrastim biosimilars are also approved for use in Europe. While other forms of G-CSF, including biosimilars, are administered by a course of daily injections, pegfilgrastim allows once-per-cycle administration. Choice of formulation remains a matter for individual clinical judgement. Evidence from multiple low level studies derived from audit data and clinical practice suggests that some patients receive suboptimal daily G-CSFs; the use of pegfilgrastim may avoid this problem.

Lenograstim: a review of its use in chemotherapy-induced neutropenia, for acceleration of neutrophil recovery following haematopoietic stem cell transplantation and in peripheral blood stem cell mobilization.
Gillian M Keating.
Drugs, 2011 Apr 21; 71(6). PMID: 21504247
Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.
Nicole M Kuderer, Gary H Lyman.
J Natl Cancer Inst, 2011 Jun 15; 103(12). PMID: 21670422    Free PMC article.
Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis.
Nuttapong Ngamphaiboon, Tracey L O'Connor, +2 authors, Ellen B Kossoff.
Med Oncol, 2011 Aug 06; 29(3). PMID: 21818673
Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis.
Katy L Cooper, Jason Madan, +2 authors, Ron L Akehurst.
BMC Cancer, 2011 Sep 29; 11. PMID: 21943360    Free PMC article.
Systematic Review.
Lecture: management of chemotherapy-induced febrile neutropenia; guidelines and colony stimulating factors.
Giuseppe Procopio, Monica Niger, Isabella Testa.
Neurol Sci, 2011 Oct 18; 32 Suppl 2. PMID: 22002072
Re: personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.
Arnold L Potosky, Jennifer L Malin, +2 authors, Jane C Weeks.
J Natl Cancer Inst, 2011 Nov 01; 103(24). PMID: 22036767    Free PMC article.
Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma.
Ruth Pettengell, Hans E Johnsen, +8 authors, Ulrich Jaeger.
Support Care Cancer, 2011 Nov 22; 20(3). PMID: 22101611    Free PMC article.
Colony stimulating factors (CSF) biosimilars. Progress?
Florian Scotté, Vincent Launay-Vacher, Jean-Baptiste Rey.
Target Oncol, 2012 Jan 18; 7 Suppl 1. PMID: 22249656
Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis.
Tallal Younis, Daniel Rayson, Kara Thompson.
Support Care Cancer, 2012 Jan 19; 20(10). PMID: 22252548
Systematic Review.
Presently available biosimilars in hematology-oncology: G-CSF.
Pere Gascon.
Target Oncol, 2012 Jan 20; 7 Suppl 1. PMID: 22258705    Free PMC article.
What do prescribers think of biosimilars?
M S Aapro.
Target Oncol, 2012 Jan 20; 7 Suppl 1. PMID: 22258706
A way forward on the medically appropriate use of white cell growth factors.
Thomas J Smith, Bruce E Hillner.
J Clin Oncol, 2012 Mar 01; 30(14). PMID: 22370327    Free PMC article.
Hematopoietic growth factors: personalization of risks and benefits.
Shannon Puhalla, Saveri Bhattacharya, Nancy E Davidson.
Mol Oncol, 2012 Apr 14; 6(2). PMID: 22497867    Free PMC article.
Pharmacoeconomics of the myeloid growth factors: a critical and systematic review.
Bradford R Hirsch, Gary H Lyman.
Pharmacoeconomics, 2012 May 01; 30(6). PMID: 22540394
Systematic Review.
SEOM clinical guidelines for myeloid growth factors.
José Muñoz Langa, Pere Gascón, Javier de Castro, SEOM (Spanish Society of Clinical Oncology).
Clin Transl Oncol, 2012 Jun 23; 14(7). PMID: 22721792
Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) guideline for prophylaxis with granulocyte colony-stimulating factors (G-CSF) in gynecologic malignancies, including breast cancer.
Edgar Petru, Alain Gustave Zeimet, +9 authors, Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO).
Wien Klin Wochenschr, 2012 Jun 29; 124(11-12). PMID: 22739650
Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours.
G Freyer, N Isambert, +8 authors, P Fumoleau.
Br J Cancer, 2012 Jul 14; 107(4). PMID: 22790797    Free PMC article.
Guideline-Based Peer-to-Peer Consultation Optimizes Pegfilgrastim Use With No Adverse Clinical Consequences.
Marc L Fishman, Akhil Kumar, +2 authors, William J M Hrushesky.
J Oncol Pract, 2012 Sep 04; 8(3 Suppl). PMID: 22942828    Free PMC article.
Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis.
Sophie Lee, Angela Knox, +3 authors, Samar Issa.
Support Care Cancer, 2012 Sep 14; 21(3). PMID: 22972488
Predictors of response of patients with solid tumors to granulocyte colony-stimulating factor.
Hiroaki Ohnaka, Hitoshi Tsukamoto, +5 authors, Mikio Masada.
Int J Clin Pharm, 2012 Sep 27; 35(1). PMID: 23011270
Management of advanced prostate cancer in senior adults: the new landscape.
Matti S Aapro.
Oncologist, 2012 Oct 04; 17 Suppl 1. PMID: 23015681    Free PMC article.
The importance of supportive care in optimizing treatment outcomes of patients with advanced prostate cancer.
Florian Scotté.
Oncologist, 2012 Oct 04; 17 Suppl 1. PMID: 23015682    Free PMC article.
A non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology centre.
Karl Verpoort, Thomas M Möhler.
Ther Adv Med Oncol, 2012 Nov 03; 4(6). PMID: 23118804    Free PMC article.
Chemotherapy-Induced Neutropenia in HIV Positive Patients with Lymphoma: Comparison of Pegfilgrastim with Daily Filgrastim Administration.
Luciana Teofili, Immacolata Izzi, +4 authors, Katleen de Gaetano Donati.
Mediterr J Hematol Infect Dis, 2012 Nov 22; 4(1). PMID: 23170191    Free PMC article.
A randomized, non-inferiority study comparing efficacy and safety of a single dose of pegfilgrastim versus daily filgrastim in pediatric patients after autologous peripheral blood stem cell transplant.
Simone Cesaro, Francesca Nesi, +4 authors, Elisabetta Calore.
PLoS One, 2013 Jan 12; 8(1). PMID: 23308174    Free PMC article.
Supportive therapy in medical therapy of head and neck tumors.
Hartmut Link.
GMS Curr Top Otorhinolaryngol Head Neck Surg, 2013 Jan 16; 11. PMID: 23320053    Free PMC article.
Neutropenia and G-CSF in lymphoproliferative diseases.
Roberto Ria, Antonia Reale, +2 authors, Angelo Vacca.
Hematology, 2013 Jan 17; 18(3). PMID: 23321273    Free PMC article.
Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review.
Martin Frank, Thomas Mittendorf.
Pharmacoeconomics, 2013 Jan 23; 31(3). PMID: 23338963
Systematic Review.
Analysis of chemotherapy-induced neutropenia and optimal timing for prophylactic use of G-CSF in B-cell non-Hodgkin lymphoma patients treated with R-CHOP.
Hisaharu Shikata, Yoshihiro Yakushijin, +2 authors, Masaki Yasukawa.
Int J Clin Oncol, 2013 Feb 06; 19(1). PMID: 23380958
Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
S Neumann, S W Krause, +4 authors, German Society of Hematology and Oncology (DGHO).
Ann Hematol, 2013 Feb 16; 92(4). PMID: 23412562    Free PMC article.
Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes.
Jason D Wright, Alfred I Neugut, +5 authors, Dawn L Hershman.
JAMA Intern Med, 2013 Mar 06; 173(7). PMID: 23460379    Free PMC article.
Breakthrough febrile neutropenia and associated complications among elderly cancer patients receiving myelosuppressive chemotherapy for solid tumors and lymphomas.
Alexandre Chan, Chee Ping Lee, Joen Chiang, Raymond Ng.
Support Care Cancer, 2013 Mar 09; 21(8). PMID: 23471537
Colony-stimulating factors for febrile neutropenia during cancer therapy.
Charles L Bennett, Benjamin Djulbegovic, LeAnn B Norris, James O Armitage.
N Engl J Med, 2013 Mar 22; 368(12). PMID: 23514290    Free PMC article.
Incidence and management of infections in patients with acute leukemia following chemotherapy in general wards.
Sasmita Biswal, Chaitali Godnaik.
Ecancermedicalscience, 2013 May 02; 7. PMID: 23634180    Free PMC article.
Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia.
A K Altwairgi, W M Hopman, M Mates.
Curr Oncol, 2013 Jun 06; 20(3). PMID: 23737687    Free PMC article.
Incidence and predictors of febrile neutropenia during chemotherapy in patients with head and neck cancer.
Yukinori Takenaka, Hironori Cho, +3 authors, Hidenori Inohara.
Support Care Cancer, 2013 Jun 12; 21(10). PMID: 23748486
Follow-on biologics in oncology - the need for global and local regulations.
Iwona Hus.
Contemp Oncol (Pozn), 2012 Jan 01; 16(6). PMID: 23788931    Free PMC article.
Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients.
Mélanie L Pastor, Céline M Laffont, +3 authors, Didier Concordet.
Pharm Res, 2013 Jun 27; 30(11). PMID: 23801085
Filgrastim XM02 (Tevagrastim®) after autologous stem cell transplantation compared to lenograstim: favourable cost-efficacy analysis.
A Gardellini, F Gigli, +5 authors, D Laszlo.
Ecancermedicalscience, 2013 Jul 03; 7. PMID: 23818939    Free PMC article.
Top-down MS for rapid methionine oxidation site assignment in filgrastim.
Johann Holzmann, Anna Hausberger, Alfred Rupprechter, Hansjoerg Toll.
Anal Bioanal Chem, 2013 Jul 09; 405(21). PMID: 23831755    Free PMC article.
Clinical experience with Zarzio® in Europe: what have we learned?
Pere Gascón, Hans Tesch, +7 authors, Matthew Turner.
Support Care Cancer, 2013 Aug 02; 21(10). PMID: 23903799    Free PMC article.
Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic.
Geralyn E Waters, Patricia Corrigan, Mandy Gatesman, Thomas J Smith.
J Oncol Pract, 2013 Aug 15; 9(4). PMID: 23942922    Free PMC article.
Febrile neutropenia in hematologic malignancies.
Michael K Keng, Mikkael A Sekeres.
Curr Hematol Malig Rep, 2013 Aug 31; 8(4). PMID: 23990311
Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
Sabine Mousset, Dieter Buchheidt, +17 authors, Angelika Böhme.
Ann Hematol, 2013 Sep 13; 93(1). PMID: 24026426    Free PMC article.
Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practice.
K Krzemieniecki, P Sevelda, +7 authors, J Maenpaa.
Support Care Cancer, 2013 Oct 25; 22(3). PMID: 24154740    Free PMC article.
Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia.
Didier Kamioner, Stefan Fruehauf, +3 authors, Christian Berthou.
BMC Cancer, 2013 Nov 19; 13. PMID: 24237790    Free PMC article.
Clinical efficacy of adjunctive G-CSF on solid tumor and lymphoma patients with established febrile neutropenia.
Alexandre Chan, Qi Xuan Wong, +2 authors, Li Yang Hsu.
Support Care Cancer, 2013 Dec 10; 22(4). PMID: 24317848
Granulocyte colony-stimulating factor (G-CSF) patterns of use in cancer patients receiving myelosuppressive chemotherapy.
Mi Rim Choi, Craig A Solid, +4 authors, Thomas J Arneson.
Support Care Cancer, 2014 Feb 05; 22(6). PMID: 24492928
Impact of granulocyte colony-stimulating factors in metastatic colorectal cancer patients.
A Amadio, R Burkes, +2 authors, B Coleman.
Curr Oncol, 2014 Feb 14; 21(1). PMID: 24523621    Free PMC article.
Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer.
J A Pérez-Fidalgo, B Bermejo, +7 authors, A Lluch.
Clin Transl Oncol, 2014 Feb 18; 16(9). PMID: 24532305    Free PMC article.
Leukocytoclastic vasculitis as a complication of recombinant granulocyte colony-stimulating factor therapy in a heart transplant patient.
Giovanbattista Ippoliti, Marco Paulli, +2 authors, Andrea Maria D'Armini.
Case Rep Transplant, 2014 Mar 07; 2014. PMID: 24600524    Free PMC article.
Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors.
Alena M Pfeil, Christof Vulsteke, +8 authors, Hans Wildiers.
BMC Cancer, 2014 Mar 20; 14. PMID: 24641830    Free PMC article.
Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma.
Wendy J Langeberg, Conchitina C Siozon, +2 authors, Victoria M Chia.
Support Care Cancer, 2014 Mar 22; 22(8). PMID: 24652049
Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study.
Eva Culakova, Ramya Thota, +5 authors, Gary H Lyman.
Cancer Med, 2014 Apr 08; 3(2). PMID: 24706592    Free PMC article.
Present status of adjuvant chemotherapy for elderly breast cancer patients.
Sibylle Loibl, Mattea Reinisch.
Breast Care (Basel), 2012 Dec 01; 7(6). PMID: 24715824    Free PMC article.
Side effects of standard adjuvant and neoadjuvant chemotherapy regimens according to age groups in primary breast cancer.
Mattea Reinisch, Gunter von Minckwitz, +6 authors, Sibylle Loibl.
Breast Care (Basel), 2014 Apr 10; 8(1). PMID: 24715845    Free PMC article.
Feasibility and safety of a reduced duration of therapy of colony-stimulating factor in a dose-dense regimen.
Luigi Rigacci, Benedetta Puccini, +4 authors, Alberto Bosi.
Support Care Cancer, 2014 Apr 18; 22(9). PMID: 24740178    Free PMC article.
Use of colony-stimulating factor in patients with ovarian cancer receiving paclitaxel and carboplatin in Japan.
Kenichi Harano, Akihiro Hirakawa, +3 authors, Noriyuki Katsumata.
J Gynecol Oncol, 2014 Apr 25; 25(2). PMID: 24761216    Free PMC article.
The use of granulocyte colony-stimulating factors in a Canadian outpatient setting.
S Fine, M Koo, +4 authors, N Mittmann.
Curr Oncol, 2014 Apr 26; 21(2). PMID: 24764708    Free PMC article.
Chemotherapy treatment patterns and neutropenia management in gastric cancer.
Ewa Kalinka-Warzocha, Javier Gallego Plazas, +5 authors, Rodolfo Passalacqua.
Gastric Cancer, 2014 May 06; 18(2). PMID: 24792482
Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study.
B Linot, P Augereau, +2 authors, O Capitain.
Support Care Cancer, 2014 May 14; 22(10). PMID: 24821366
Enhanced heterologous expression of biologically active human granulocyte colony stimulating factor in transgenic tobacco BY-2 cells by localization to endoplasmic reticulum.
Nisha R Nair, M Chidambareswaren, S Manjula.
Mol Biotechnol, 2014 May 23; 56(9). PMID: 24845752
Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib.
R Donald Harvey.
Clin Pharmacol, 2014 May 24; 6. PMID: 24855395    Free PMC article.
Cost-effectiveness analysis of docetaxel versus weekly paclitaxel in adjuvant treatment of regional breast cancer in New Zealand.
Rachel Webber-Foster, Giorgi Kvizhinadze, Gareth Rivalland, Tony Blakely.
Pharmacoeconomics, 2014 May 27; 32(7). PMID: 24859241
Presentation and management of docetaxel-related adverse effects in patients with breast cancer.
Maria Y Ho, John R Mackey.
Cancer Manag Res, 2014 Jun 07; 6. PMID: 24904223    Free PMC article.
Clinical predictive models for chemotherapy-induced febrile neutropenia in breast cancer patients: a validation study.
Kai Chen, Xiaolan Zhang, +4 authors, Xiaogeng Deng.
PLoS One, 2014 Jun 20; 9(6). PMID: 24945817    Free PMC article.
Bioclinical parameters driving decision-making of subsequent lines of treatment in metastatic castration-resistant prostate cancer.
A Irelli, G Bruera, +5 authors, E Ricevuto.
Biomed Res Int, 2014 Jun 28; 2014. PMID: 24971356    Free PMC article.
Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment.
Hazem Assi, Joshua Murray, Laura Boyle, Daniel Rayson.
Support Care Cancer, 2014 Jul 06; 22(12). PMID: 24996828
Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer.
Masaki Shiota, Akira Yokomizo, +4 authors, Seiji Naito.
Support Care Cancer, 2014 Jul 06; 22(12). PMID: 24996830
Myeloid toxicity of cancer treatment.
Sandra Kurtin.
J Adv Pract Oncol, 2012 Jul 01; 3(4). PMID: 25031949    Free PMC article.
Model-based approach to early predict prolonged high grade neutropenia in carboplatin-treated patients and guide G-CSF prophylactic treatment.
Mélanie L Pastor, Céline M Laffont, +2 authors, Didier Concordet.
Pharm Res, 2014 Sep 05; 32(2). PMID: 25186439
A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy.
Anton Buchner, Reiner Elsässer, Peter Bias.
Breast Cancer Res Treat, 2014 Sep 28; 148(1). PMID: 25261291    Free PMC article.
Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.
Alena M Pfeil, Kim Allcott, +3 authors, Zsolt Szabo.
Support Care Cancer, 2014 Oct 07; 23(2). PMID: 25284721
Systematic Review.
Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia.
Sol Cortés de Miguel, Miguel Ángel Calleja-Hernández, Salomón Menjón-Beltrán, Inmaculada Vallejo-Rodríguez.
Support Care Cancer, 2014 Oct 07; 23(2). PMID: 25284722
Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality.
Carmel Jacobs, Ian D Graham, +4 authors, Mark Clemons.
PLoS One, 2014 Oct 21; 9(10). PMID: 25329669    Free PMC article.
Adjuvant Docetaxel and Cyclophosphamide (DC) with prophylactic granulocyte colony-stimulating factor (G-CSF) on days 8 &12 in breast cancer patients: a retrospective analysis.
Rinat Yerushalmi, Hadar Goldvaser, +10 authors, Salomon M Stemmer.
PLoS One, 2014 Oct 21; 9(10). PMID: 25330205    Free PMC article.
Laparoscopic cholecystectomy for acalculous cholecystitis in a neutropenic patient after chemotherapy for acute lymphoblastic leukemia.
Konrad Pielaciński, Anna Ejduk, Tadeusz Wróblewski, Andrzej B Szczepanik.
Wideochir Inne Tech Maloinwazyjne, 2014 Oct 23; 9(3). PMID: 25337176    Free PMC article.
Management of breast cancer patients with chemotherapy-induced neutropenia or febrile neutropenia.
Caterina Fontanella, Silvia Bolzonello, Bianca Lederer, Giuseppe Aprile.
Breast Care (Basel), 2014 Nov 19; 9(4). PMID: 25404882    Free PMC article.
Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Yong Won Choi, Seong Hyun Jeong, +5 authors, Joon Seong Park.
J Korean Med Sci, 2014 Nov 20; 29(11). PMID: 25408580    Free PMC article.
G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use.
Gisoo Barnes, Ashutosh Pathak, Lee Schwartzberg.
Cancer Med, 2014 Nov 21; 3(6). PMID: 25410813    Free PMC article.
A modified filgrastim regimen does not reduce pain burden compared to pegfilgrastim in women receiving chemotherapy for non-metastatic breast cancer.
Mova Leung, Joy Florendo, +5 authors, Glenn Jones.
Support Care Cancer, 2014 Nov 26; 23(6). PMID: 25421443
Moxibustion for the treatment of chemotherapy-induced leukopenia: a systematic review of randomized clinical trials.
Tae-Young Choi, Myeong Soo Lee, Edzard Ernst.
Support Care Cancer, 2014 Dec 05; 23(6). PMID: 25471180
Systematic Review.
A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Yun Wang, Jørn Herrstedt, +5 authors, Gunnar Kristensen.
BMC Cancer, 2014 Dec 17; 14. PMID: 25494701    Free PMC article.
Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy.
Yoshimasa Kosaka, Yoshiaki Rai, +7 authors, Kazuo Tamura.
Support Care Cancer, 2015 Jan 13; 23(4). PMID: 25576433    Free PMC article.
Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens for breast cancer.
Peter Gilbar, Natacha Sorour, Ian McPherson.
Support Care Cancer, 2015 Jan 13; 23(3). PMID: 25577506
Clinical analysis of febrile neutropenia in urological anticancer chemotherapy: retrospective single center study.
Naotaka Nishiyama, Satoshi Takahashi, +4 authors, Naoya Masumori.
Int J Clin Oncol, 2015 Feb 06; 20(5). PMID: 25652906
Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial.
Norikazu Masuda, Yutaka Tokuda, +3 authors, Kazuo Tamura.
Support Care Cancer, 2015 Mar 04; 23(10). PMID: 25733000    Free PMC article.
Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland.
Marek Wojtukiewicz, Ewa Chmielowska, +5 authors, Elżbieta Kosno-Kruszewska.
Contemp Oncol (Pozn), 2014 Jan 01; 18(6). PMID: 25784841    Free PMC article.
Clinical practice in secondary prophylaxis and management of febrile neutropenia in Poland: results of the febrile neutropenia awareness project.
Marek Wojtukiewicz, Ewa Chmielowska, +5 authors, Elżbieta Kosno-Kruszewska.
Contemp Oncol (Pozn), 2014 Jan 01; 18(6). PMID: 25784842    Free PMC article.
Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?
Gary H Lyman, David C Dale, +4 authors, Jeffrey Crawford.
Cancer Med, 2015 Mar 27; 4(8). PMID: 25810005    Free PMC article.
An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy.
Wei Zhang, Zhiwei Jiang, +2 authors, Jielai Xia.
Med Oncol, 2015 Mar 31; 32(5). PMID: 25820754
The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.
Li Wang, Onur Baser, +2 authors, Richard Barron.
Support Care Cancer, 2015 Mar 31; 23(11). PMID: 25821144    Free PMC article.
Systematic Review.
Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14.
Antonio Gutiérrez, Leyre Bento, +19 authors, Joan Besalduch.
PLoS One, 2015 Apr 25; 10(4). PMID: 25909361    Free PMC article.
Phase II dose-finding study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy.
Oleg Gladkov, Vladimir Moiseyenko, +5 authors, Noa Avisar.
Med Oncol, 2015 May 15; 32(6). PMID: 25966791
A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511).
Taofeek K Owonikoko, Suzanne E Dahlberg, +7 authors, Suresh S Ramalingam.
Lung Cancer, 2015 May 20; 89(1). PMID: 25985977    Free PMC article.
Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies.
I M Bondarenko, P Bias, A Buchner.
Support Care Cancer, 2015 May 31; 24(1). PMID: 26024743
Febrile neutropenia in chemotherapy treated small-cell lung cancer patients.
Renata Rezonja Kukec, Iztok Grabnar, +3 authors, Tanja Cufer.
Radiol Oncol, 2015 Jun 02; 49(2). PMID: 26029029    Free PMC article.
Induction chemotherapy with concurrent chemoradiotherapy versus concurrent chemoradiotherapy for locally advanced squamous cell carcinoma of head and neck: a meta-analysis.
Lijuan Zhang, Nan Jiang, +3 authors, Yue Zhao.
Sci Rep, 2015 Jun 05; 5. PMID: 26041604    Free PMC article.
In vitro and in vivo study on the effect of antifungal agents on hematopoietic cells in mice.
Maria Samalidou, Dimitris Bougiouklis, +6 authors, Damianos Sotiropoulos.
Exp Biol Med (Maywood), 2015 Jun 17; 240(12). PMID: 26080459    Free PMC article.
Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy--a representative sample survey in Germany.
Hartmut Link, J Nietsch, +2 authors, Supportive Care Group (ASORS) of the German Cancer Society (DKG).
Support Care Cancer, 2015 Jun 18; 24(1). PMID: 26081593
Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
Chris Skedgel, Daniel Rayson, Tallal Younis.
Support Care Cancer, 2015 Jun 18; 24(1). PMID: 26081595
Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.
Oleg A Gladkov, Anton Buchner, +2 authors, Reiner Elsässer.
Support Care Cancer, 2015 Jun 21; 24(1). PMID: 26092233
Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
M Brito, S Esteves, +2 authors, A Moreira.
Support Care Cancer, 2015 Jun 27; 24(2). PMID: 26111956
Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
K Blackwell, V Semiglazov, +8 authors, N Harbeck.
Ann Oncol, 2015 Jul 01; 26(9). PMID: 26122726    Free PMC article.
Epidemiology and characteristics of febrile neutropenia in oncology patients from Spanish tertiary care hospitals: PINNACLE study.
Javier DE Castro Carpeño, Pere Gascón-Vilaplana, +8 authors, Francisco José Rebollo Laserna.
Mol Clin Oncol, 2015 Jul 03; 3(3). PMID: 26137294    Free PMC article.
Adjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care?
Anna Rachelle Mislang, Laura Biganzoli.
Cancers (Basel), 2015 Jul 08; 7(3). PMID: 26151681    Free PMC article.
Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy.
Constantin Volovat, Igor M Bondarenko, +4 authors, Udo Müller.
Springerplus, 2015 Jul 15; 4. PMID: 26155455    Free PMC article.
Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim.
H Xu, Q Gong, +2 authors, J H Page.
Support Care Cancer, 2015 Jul 15; 24(2). PMID: 26162536
Understanding the risk for infection in patients with neutropenia.
Jean A Klastersky, Anne-Pascale Meert.
Intensive Care Med, 2015 Jul 15; 42(2). PMID: 26170099
The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study.
Eva Culakova, Marek S Poniewierski, +3 authors, Gary H Lyman.
Springerplus, 2015 Aug 08; 4. PMID: 26251780    Free PMC article.
Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy.
Yasunori Hashiguchi, Mari Kasai, +3 authors, Toshiyuki Sumi.
Anticancer Drugs, 2015 Aug 13; 26(10). PMID: 26267078    Free PMC article.
Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).
Pere Gascón, Matti Aapro, +6 authors, Ivo Abraham.
Support Care Cancer, 2015 Aug 27; 24(2). PMID: 26306517
Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.
Gilles Freyer, Ewa Kalinka-Warzocha, +9 authors, Zsolt Szabo.
Med Oncol, 2015 Sep 01; 32(10). PMID: 26315712
Effects of Traditional Chinese Medicine on Chemotherapy-Induced Myelosuppression and Febrile Neutropenia in Breast Cancer Patients.
Huan Tian, Wei Qin, +5 authors, Fengxi Su.
Evid Based Complement Alternat Med, 2015 Sep 09; 2015. PMID: 26347793    Free PMC article.
Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors.
George Dranitsaris, Sasha Mazzarello, +3 authors, Mark Clemons.
Support Care Cancer, 2015 Sep 19; 24(4). PMID: 26381427
A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09.
Ki Hyeong Lee, Ji-Yeon Kim, +15 authors, Seock-Ah Im.
Support Care Cancer, 2015 Oct 02; 24(4). PMID: 26423618    Free PMC article.
Attitudes and practice patterns for maintaining relative dose intensity of chemotherapy in outpatient clinics: results of a Japanese web-based survey.
Hitomi Sakai, Noriyuki Katsumata, Genmu Kadokura.
BMC Cancer, 2015 Oct 07; 15. PMID: 26438185    Free PMC article.
A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial.
Jean-Baptiste Bachet, Benoist Chibaudel, +5 authors, GERCOR group.
BMC Cancer, 2015 Oct 09; 15. PMID: 26445094    Free PMC article.
Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer.
Gregory S Calip, Judith A Malmgren, +2 authors, Henry G Kaplan.
Breast Cancer Res Treat, 2015 Oct 10; 154(1). PMID: 26450505    Free PMC article.
Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement.
Edgar Petru, Christian F Singer, +12 authors, Alain-Gustave Zeimet.
Wien Med Wochenschr, 2015 Oct 17; 165(19-20). PMID: 26471371
Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study.
Sophie Nahon, Mansour Rastkhah, +3 authors, Jean-Luc Labourey.
Support Care Cancer, 2015 Oct 29; 24(5). PMID: 26507190    Free PMC article.
Multicentre, Prospective Observational Study of Pegfilgrastim Primary Prophylaxis in Patients at High Risk of Febrile Neutropenia in Poland: PROFIL Study.
Wojciech Jurczak, Ewa Kalinka-Warzocha, +3 authors, Karolina Wieruszewska.
Contemp Oncol (Pozn), 2015 Nov 12; 19(3). PMID: 26557762    Free PMC article.
The evolving role of biosimilars in haematology-oncology: a practical perspective.
Pere Gascon.
Ther Adv Hematol, 2015 Dec 02; 6(6). PMID: 26622996    Free PMC article.
Characteristic clinical features of Aspergillus appendicitis: Case report and literature review.
Mihajlo Gjeorgjievski, Mitual B Amin, Mitchell S Cappell.
World J Gastroenterol, 2015 Dec 08; 21(44). PMID: 26640349    Free PMC article.
A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel.
Oleg Gladkov, Vladimir Moiseyenko, +4 authors, Noa Avisar.
Oncologist, 2015 Dec 17; 21(1). PMID: 26668251    Free PMC article.
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Nicholas D James, Matthew R Sydes, +45 authors, STAMPEDE investigators.
Lancet, 2016 Jan 01; 387(10024). PMID: 26719232    Free PMC article.
Highly Cited.
Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy.
Radosław Mądry, Lidia Popławska, +10 authors, Christine Staudigl.
Wien Klin Wochenschr, 2016 Jan 10; 128(7-8). PMID: 26745973    Free PMC article.
Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients.
Nobuyuki Horita, Masaki Yamamoto, +13 authors, Takeshi Kaneko.
Sci Rep, 2016 Jan 12; 6. PMID: 26750506    Free PMC article.
Systematic Review.
Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor.
Ruth Pettengell, Peter Bias, Udo Mueller, Nicole Lang.
Support Care Cancer, 2016 Jan 19; 24(6). PMID: 26780505
Granulocyte growth factor use in elderly patients with non-Hodgkin's lymphoma in the United States: adherence to guidelines and comparative effectiveness.
Linda S Elting, Ying Xu, Mariana Chavez-MacGregor, Sharon H Giordano.
Support Care Cancer, 2016 Jan 23; 24(6). PMID: 26797253
Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients.
Roberto Guariglia, Maria Carmen Martorelli, +3 authors, Pellegrino Musto.
Biologics, 2016 Feb 10; 10. PMID: 26858523    Free PMC article.
Serious neutropenia following neoadjuvant chemotherapy for locally advanced breast cancer: A case report.
Zhen Wang, Jun-Qiang Chen, Jin-Lu Liu, Xin-Gan Qin.
Oncol Lett, 2016 Feb 20; 11(2). PMID: 26893787    Free PMC article.
Biosimilars in the management of neutropenia: focus on filgrastim.
Désirée Caselli, Simone Cesaro, Maurizio Aricò.
Biologics, 2016 Mar 05; 10. PMID: 26937170    Free PMC article.
The changing landscape of biosimilars in rheumatology.
Thomas Dörner, Vibeke Strand, +7 authors, Gerd R Burmester.
Ann Rheum Dis, 2016 Mar 11; 75(6). PMID: 26964144    Free PMC article.
Highly Cited. Review.
Bloodstream infections in neutropenic cancer patients: A practical update.
Giulia Gustinetti, Malgorzata Mikulska.
Virulence, 2016 Mar 24; 7(3). PMID: 27002635    Free PMC article.
Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
Nadia Harbeck, Oleg Lipatov, +7 authors, Kimberly Blackwell.
Future Oncol, 2016 Mar 30; 12(11). PMID: 27020170    Free PMC article.
Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy.
Chang Gon Kim, Joohyuk Sohn, +8 authors, Gun Min Kim.
J Breast Cancer, 2016 Apr 12; 19(1). PMID: 27064666    Free PMC article.
Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide.
Jungsil Ro, Fiona Tsui-Fen Cheng, +5 authors, Asian Working Group for Eribulin Clinical Guide.
J Breast Cancer, 2016 Apr 12; 19(1). PMID: 27066091    Free PMC article.
A randomized, double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma.
Kohmei Kubo, Yasuhiko Miyazaki, +5 authors, Kazuo Tamura.
Br J Haematol, 2016 Apr 14; 174(4). PMID: 27072050    Free PMC article.
Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient setting.
Eiseki Usami, Michio Kimura, +3 authors, Tomoaki Yoshimura.
Mol Clin Oncol, 2016 Apr 14; 4(4). PMID: 27073670    Free PMC article.
Prognostic Value of Neutrophil-Related Factors in Locally Advanced Cervical Squamous Cell Carcinoma Patients Treated with Cisplatin-Based Concurrent Chemoradiotherapy.
Yan-Yang Wang, Zhou-Lan Bai, +4 authors, Hong Zhe.
Dis Markers, 2016 Apr 19; 2016. PMID: 27087737    Free PMC article.
A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial.
Kimberly Blackwell, Roman Donskih, +7 authors, Nadia Harbeck.
Oncologist, 2016 Apr 20; 21(7). PMID: 27091420    Free PMC article.
Tarik Catic, Alma Mekic-Abazovic, Samra Sulejmanovic.
Mater Sociomed, 2016 May 06; 28(2). PMID: 27147916    Free PMC article.
A dimeric peptide with erythropoiesis-stimulating activity uniquely affects erythropoietin receptor ligation and cell surface expression.
Rakesh Verma, Jennifer M Green, Peter J Schatz, Don M Wojchowski.
Exp Hematol, 2016 May 14; 44(8). PMID: 27174804    Free PMC article.
Efficacy and safety of acupuncture for chemotherapy-induced leucopoenia: protocol for a systematic review.
Jiayun Nian, Xu Sun, +6 authors, Ganlin Zhang.
BMJ Open, 2016 May 28; 6(5). PMID: 27231002    Free PMC article.
Granulocyte Colony-Stimulating Factor Use in a Large Iranian Hospital: Comparison with American Society of Clinical Oncology (ASCO) Clinical Practice Guideline.
Sarah Mousavi, Mina Dadpoor, Farzaneh Ashrafi.
Int J Hematol Oncol Stem Cell Res, 2016 Jun 03; 10(2). PMID: 27252808    Free PMC article.
Lack of Effectiveness of Neutropenic Diet and Social Restrictions as Anti-Infective Measures in Children With Acute Myeloid Leukemia: An Analysis of the AML-BFM 2004 Trial.
Lars Tramsen, Emilia Salzmann-Manrique, +5 authors, Thomas Lehrnbecher.
J Clin Oncol, 2016 Jun 09; 34(23). PMID: 27269945    Free PMC article.
Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies.
Yanli Li, Zandra Klippel, +3 authors, John H Page.
Support Care Cancer, 2016 Jun 10; 24(10). PMID: 27278272
Supportive Care in Older Adults with Cancer: Across the Continuum.
Thuy Koll, Mackenzi Pergolotti, +5 authors, Christopher B Steer.
Curr Oncol Rep, 2016 Jun 28; 18(8). PMID: 27342609    Free PMC article.
Urothelial carcinoma management in elderly or unfit patients.
Joaquim Bellmunt, Nicolas Mottet, Maria De Santis.
EJC Suppl, 2016 Jul 01; 14(1). PMID: 27358584    Free PMC article.
Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?
Filipe C Araújo, João Gonçalves, João Eurico Fonseca.
Curr Rheumatol Rep, 2016 Jul 13; 18(8). PMID: 27402107
Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies.
Evelien Moorkens, Clara Jonker-Exler, +3 authors, Arnold G Vulto.
Front Pharmacol, 2016 Jul 23; 7. PMID: 27445826    Free PMC article.
Individual level covariate adjusted conditional autoregressive (indiCAR) model for disease mapping.
Md Hamidul Huque, Craig Anderson, Richard Walton, Louise Ryan.
Int J Health Geogr, 2016 Jul 31; 15(1). PMID: 27473270    Free PMC article.
Performance of the clinical index of stable febrile neutropenia (CISNE) in different types of infections and tumors.
A Carmona-Bayonas, P Jiménez-Fonseca, +20 authors, Supportive Care Working Group of the Spanish Society of Medical Oncology (SEOM).
Clin Transl Oncol, 2016 Aug 16; 19(3). PMID: 27525978
Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR).
Alberto Bongiovanni, Manuela Monti, +9 authors, Toni Ibrahim.
Support Care Cancer, 2016 Aug 29; 25(1). PMID: 27568305
Response of an oscillatory differential delay equation to a single stimulus.
Michael C Mackey, Marta Tyran-Kamińska, Hans-Otto Walther.
J Math Biol, 2016 Sep 11; 74(5). PMID: 27613016
A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer.
K H Park, S Lee, +11 authors, Jae Hong Seo.
Support Care Cancer, 2016 Oct 07; 25(2). PMID: 27709313
Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study.
Stefan Fruehauf, Burkhard Otremba, Oliver Stötzer, Christine Rudolph.
Adv Ther, 2016 Oct 28; 33(11). PMID: 27743353    Free PMC article.
Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study).
M Aapro, H Ludwig, +7 authors, I Abraham.
Ann Oncol, 2016 Oct 30; 27(11). PMID: 27793849    Free PMC article.
G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy.
Umberto Vitolo, Francesco Angrili, +2 authors, Massimo Federico.
Med Oncol, 2016 Nov 09; 33(12). PMID: 27822615
Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
Kelly Fust, Xiaoyan Li, +7 authors, Gary H Lyman.
Pharmacoeconomics, 2016 Dec 09; 35(4). PMID: 27928760    Free PMC article.
Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494).
Vicki A Morrison, Edie A Weller, +4 authors, Bruce A Peterson.
Leuk Lymphoma, 2016 Dec 15; 58(8). PMID: 27967294    Free PMC article.
Neutropenic enterocolitis.
Fabio G Rodrigues, Giovanna Dasilva, Steven D Wexner.
World J Gastroenterol, 2017 Jan 21; 23(1). PMID: 28104979    Free PMC article.
Interstitial pneumonia following administration of pegfilgrastim during carboplatin and etoposide chemotherapy for small-cell lung cancer.
Masayuki Shirasawa, Yoshiro Nakahara, +7 authors, Noriyuki Masuda.
Mol Clin Oncol, 2017 Jan 21; 5(6). PMID: 28105350    Free PMC article.
Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study.
Carsten Bokemeyer, Pere Gascón, +7 authors, Karen MacDonald.
Support Care Cancer, 2017 Jan 24; 25(6). PMID: 28111718    Free PMC article.
Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions.
Xiao Jun Wang, Alexandre Chan.
Curr Oncol Rep, 2017 Mar 09; 19(3). PMID: 28271398
Hospitalizations, outcomes, and management costs of febrile neutropenia in patients from a managed care population.
Aniket A Kawatkar, Albert J Farias, +4 authors, David B Chandler.
Support Care Cancer, 2017 Apr 12; 25(9). PMID: 28397022    Free PMC article.
The Effectiveness of Febrile Neutropenia Prophylaxis with Lipegfilgrastim in Routine Clinical Practice.
Lubos Holubec, Jiri Polivka, +2 authors, Martin Safanda.
In Vivo, 2017 Apr 26; 31(3). PMID: 28438855    Free PMC article.
The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review.
Gary H Lyman, Kim Allcott, +4 authors, Derek Weycker.
Support Care Cancer, 2017 May 10; 25(8). PMID: 28484882
Systematic Review.
Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan.
Masahiro Yokoyama, Yoshiharu Kusano, +8 authors, Kiyohiko Hatake.
Support Care Cancer, 2017 May 30; 25(11). PMID: 28551843    Free PMC article.
Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events.
T Christopher Bond, Erika Szabo, +5 authors, Boxiong Tang.
J Oncol Pharm Pract, 2017 Jun 16; 24(6). PMID: 28614980    Free PMC article.
Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
K Blackwell, P Gascon, +5 authors, N Harbeck.
Ann Oncol, 2017 Jun 24; 28(9). PMID: 28637287    Free PMC article.
Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring.
Ida Netterberg, Elisabet I Nielsen, Lena E Friberg, Mats O Karlsson.
Cancer Chemother Pharmacol, 2017 Jun 29; 80(2). PMID: 28656382    Free PMC article.
Infection is an Independent Predictor of Death in Diffuse Large B Cell Lymphoma.
Claire Dendle, Michael Gilbertson, +5 authors, Zoe McQuilten.
Sci Rep, 2017 Jul 02; 7(1). PMID: 28667319    Free PMC article.
Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer.
B E P J Vriens, I J H Vriens, +9 authors, Breast Cancer Trialists’ Group of the Netherlands (BOOG).
Breast Cancer Res Treat, 2017 Jul 05; 165(3). PMID: 28674765    Free PMC article.
A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study.
Aasthaa Bansal, Sean D Sullivan, +4 authors, Scott D Ramsey.
J Comp Eff Res, 2017 Jul 08; 6(5). PMID: 28686055    Free PMC article.
Elucidation of the molecular mechanisms underlying adverse reactions associated with a kinase inhibitor using systems toxicology.
Takahiro Amemiya, Masashi Honma, +9 authors, Hiroshi Suzuki.
NPJ Syst Biol Appl, 2015 Sep 28; 1. PMID: 28725458    Free PMC article.
A Phase I study to determine safety, pharmacokinetics, and pharmacodynamics of ANF-RHO™, a novel PEGylated granulocyte colony-stimulating factor, in healthy volunteers.
Hemant Misra, John Berryman, Ronald Jubin, Abraham Abuchowski.
Invest New Drugs, 2017 Jul 29; 36(1). PMID: 28752433
Treatment effect of low intensity pulsed ultrasound on leukopenia induced by cyclophosphamide in rabbits.
Baoru Liu, Yueping Luo, +7 authors, Wenzhi Chen.
Am J Transl Res, 2017 Aug 15; 9(7). PMID: 28804549    Free PMC article.
Efficacy and safety of biosimilar filgrastim in primary and secondary prevention of febrile neutropenia.
Leszek Kraj, Joanna Krawczyk-Lipiec, Joanna Górniewska, Grzegorz Orlik.
Biomed Rep, 2017 Aug 15; 7(2). PMID: 28804626    Free PMC article.
Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis.
James Bluett, Meghna Jani, Deborah P M Symmons.
Rheumatol Ther, 2017 Aug 16; 4(2). PMID: 28808949    Free PMC article.
Danggui Buxue Decoction, a Classical Formula of Traditional Chinese Medicine, Fails to Prevent Myelosuppression in Breast Cancer Patients Treated With Adjuvant Chemotherapy: A Prospective Study.
Jin Hong, Xiaosong Chen, +11 authors, Kunwei Shen.
Integr Cancer Ther, 2017 Aug 19; 16(3). PMID: 28818031    Free PMC article.
Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.
Matti Aapro, Ralph Boccia, +10 authors, Vicente Valero.
Support Care Cancer, 2017 Aug 27; 25(11). PMID: 28842778    Free PMC article.
Clinical equivalence with G-CSF biosimilars: methodologic approach in a (neo)adjuvant setting in non-metastatic breast cancer.
A Krendyukov, M Schiestl, N Höbel, M Aapro.
Support Care Cancer, 2017 Sep 21; 26(1). PMID: 28929372    Free PMC article.
Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer.
Esse I H Akpo, Irshaad R Jansen, Edith Maes, Steven Simoens.
Front Pharmacol, 2017 Sep 29; 8. PMID: 28955224    Free PMC article.
Prognostic value of granulocyte colony-stimulating factor in patients with non-metastatic clear cell renal cell carcinoma.
Zheng Liu, Yu Zhu, +7 authors, Bo Dai.
Oncotarget, 2017 Oct 21; 8(41). PMID: 29050255    Free PMC article.
Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity.
Peter A Fasching, Lothar Häberle, +19 authors, Liewei Wang.
Oncotarget, 2017 Nov 05; 8(44). PMID: 29100455    Free PMC article.
NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim.
Jeffrey J Kirshner, Maxwell C McDonald, +7 authors, Phuong Khanh Morrow.
Support Care Cancer, 2017 Nov 18; 26(4). PMID: 29147854    Free PMC article.
A Phase II Randomized Controlled Trial: Definitive Concurrent Chemoradiotherapy with Docetaxel Plus Cisplatin versus 5-Fluorouracil plus Cisplatin in Patients with Oesophageal Squamous Cell Carcinoma.
Yujia Zhu, Wenwen Zhang, +5 authors, Yonghong Hu.
J Cancer, 2017 Nov 21; 8(18). PMID: 29151952    Free PMC article.
Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Isabel Puértolas, Alberto Frutos Pérez-Surio, +2 authors, María Del Tránsito Salvador.
Eur J Clin Pharmacol, 2017 Nov 21; 74(3). PMID: 29152672
The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin-6 and C-reactive protein by modelling.
Ida Netterberg, Mats O Karlsson, +3 authors, Lena E Friberg.
Br J Clin Pharmacol, 2017 Nov 28; 84(3). PMID: 29178353    Free PMC article.
Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?
Xavier Leleu, Francesca Gay, +2 authors, Michel Delforge.
Ann Hematol, 2017 Dec 29; 97(3). PMID: 29282494    Free PMC article.
Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.
Nadia Harbeck, Pere Gascón, +3 authors, Kimberly Blackwell.
Oncologist, 2018 Jan 11; 23(4). PMID: 29317553    Free PMC article.
Pharmacokinetic-pharmacodynamic modelling of neutrophil response to G-CSF in healthy subjects and patients with chemotherapy-induced neutropenia.
Murad Melhem, Isabelle Delor, +4 authors, Philippe Jacqmin.
Br J Clin Pharmacol, 2018 Jan 11; 84(5). PMID: 29318653    Free PMC article.
Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2.
Rastislav Bahleda, Andrea Varga, +5 authors, Jean-Pierre Delord.
Br J Cancer, 2018 Jan 18; 118(3). PMID: 29337963    Free PMC article.
Risk stratification for febrile neutropenia in patients with testicular germ cell tumors.
Angelika Terbuch, Florian Posch, +10 authors, Michael Stotz.
Cancer Med, 2018 Jan 20; 7(2). PMID: 29349917    Free PMC article.
A questionnaire survey of pharmacists regarding the clinical practice guidelines for the appropriate use of granulocyte-colony stimulating factors.
Tetsuya Sasaki, Yasuhisa Kato, +7 authors, Katsuyuki Kiura.
J Pharm Health Care Sci, 2018 Jan 30; 4. PMID: 29375887    Free PMC article.
Whom to treat? Factors associated with chemotherapy recommendations and outcomes among patients with NHL at the Uganda Cancer Institute.
Manoj Menon, Anna Coghill, +5 authors, Corey Casper.
PLoS One, 2018 Feb 02; 13(2). PMID: 29389998    Free PMC article.
Filgrastim use in patients receiving chemotherapy for early-stage breast cancer-a survey of physicians and patients.
John Hilton, Lisa Vandermeer, +8 authors, Mark Clemons.
Support Care Cancer, 2018 Feb 08; 26(7). PMID: 29411131
Development of a 'ready-to-use' tool that includes preventability, for the assessment of adverse drug events in oncology.
Guillaume Hébert, Florence Netzer, +3 authors, IATRIGGER Working Group.
Int J Clin Pharm, 2018 Feb 16; 40(2). PMID: 29446003
Adequate Neutrophil Responses and Non-Inferior Clinical Outcomes Can Be Achieved by a Two-Day Course of Low-Dose Filgrastim: A Retrospective Single Institution Experience.
Raj Singh, Henry Heisey, Ahmed G Elsayed, Maria T Tirona.
Cureus, 2018 Mar 02; 9(12). PMID: 29492357    Free PMC article.
[Oncological emergencies in chemotherapy : Febrile neutropenia, tumor lysis syndrome, and extravasation].
G von Amsberg.
Urologe A, 2018 Mar 07; 57(5). PMID: 29508029
Biology, staging, and treatment of breast cancer during pregnancy: reassessing the evidences.
Fedro Alessandro Peccatori, Matteo Lambertini, +2 authors, Giovanni Codacci-Pisanelli.
Cancer Biol Med, 2018 Mar 17; 15(1). PMID: 29545964    Free PMC article.
An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer.
Jeffrey L Vacirca, Arlene Chan, +17 authors, Lee S Schwartzberg.
Cancer Med, 2018 Mar 25; 7(5). PMID: 29573207    Free PMC article.
General recommendations paper on the management of older patients with cancer: the SEOM geriatric oncology task force's position statement.
R Gironés Sarrió, M Antonio Rebollo, +5 authors, Spanish Working Group on Geriatric Oncology of the Spanish Society of Medical Oncology (SEOM).
Clin Transl Oncol, 2018 Apr 11; 20(10). PMID: 29633183    Free PMC article.
A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim.
Cornelius F Waller, Renger G Tiessen, +9 authors, Eduardo J Pennella.
J Cancer Res Clin Oncol, 2018 Apr 20; 144(6). PMID: 29671069
Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma.
Marie Shimanuki, Yorihisa Imanishi, +19 authors, Kaoru Ogawa.
Oncotarget, 2018 May 04; 9(27). PMID: 29721176    Free PMC article.
Pegfilgrastim for primary prophylaxis of febrile neutropenia in breast cancer patients undergoing TAC chemotherapy.
Jihyoun Lee, Jong Eun Lee, +5 authors, Cheol Wan Lim.
Ann Surg Treat Res, 2018 May 08; 94(5). PMID: 29732352    Free PMC article.
Development of a simplified multivariable model to predict neutropenic complications in cancer patients undergoing chemotherapy.
Abolfazl Razzaghdoust, Bahram Mofid, Maryam Moghadam.
Support Care Cancer, 2018 May 08; 26(11). PMID: 29736867
Predictors of chemoradiation related febrile neutropenia prophylaxis in older adults - Experience from a limited resource setting.
Aparna Gangopadhyay.
Rep Pract Oncol Radiother, 2018 May 16; 23(3). PMID: 29760598    Free PMC article.
[Advanced Prostate Cancer Consensus Conference 2017 : Discussion of the recommendations for diagnosis and treatment of metastatic prostate cancer by a German panel of experts].
M Schostak, F König, +8 authors, A Heidenreich.
Urologe A, 2018 May 29; 57(7). PMID: 29808368
A comparison of the effect of xinruibai versus filgrastim on hematopoietic reconstruction after allogeneic hematopoietic stem cell transplantation.
Qixiang Ye, Hebi Jiang, Hua Jiang.
Ital J Pediatr, 2018 Jun 02; 44(1). PMID: 29855330    Free PMC article.
Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution.
Joy Bacrie, Marc Laurans, +9 authors, Delphine Lefeuvre.
Support Care Cancer, 2018 Jun 02; 26(12). PMID: 29855772
Value of incorporating newly identified risk factors into risk prediction for chemotherapy-induced febrile neutropenia.
Yanli Li, Leila Family, +4 authors, Chun R Chao.
Cancer Med, 2018 Jun 29; 7(8). PMID: 29953736    Free PMC article.
Is There a Role for Hematopoietic Growth Factors During Sepsis?
Benjamin G Chousterman, Marine Arnaud.
Front Immunol, 2018 Jul 07; 9. PMID: 29977234    Free PMC article.
Therapeutic drug monitoring of small molecule kinase inhibitors in oncology in a real-world cohort study: does age matter?
Marie-Rose B S Crombag, Jacobine G C van Doremalen, +5 authors, Alwin D R Huitema.
Br J Clin Pharmacol, 2018 Aug 02; 84(12). PMID: 30068020    Free PMC article.
Tolerability and Efficacy of Neoadjuvant Chemotherapy with a Tri-Weekly Interval Methotrexate, Doxorubicin, Vinblastine, and Cisplatin Regimen for Patients with Locally Advanced Bladder Cancer.
Satoko Arai, Tomohiko Hara, +6 authors, Hiroyuki Terakado.
Case Rep Oncol, 2018 Aug 07; 11(2). PMID: 30079018    Free PMC article.
Characterization and lymphocyte proliferation activity of an oligosaccharide degraded from Astragalus polysaccharide.
Zhen-Yuan Zhu, Jin-Yu Zhang, +3 authors, Yun Tang.
Medchemcomm, 2017 Jun 14; 8(7). PMID: 30108864    Free PMC article.
Appropriateness of granulocyte colony-stimulating factor use in patients receiving chemotherapy by febrile neutropenia risk level.
Hassam Baig, Barbara Somlo, +3 authors, Phuong K Morrow.
J Oncol Pharm Pract, 2018 Sep 12; 25(7). PMID: 30200842    Free PMC article.
Management of Febrile Neutropenia: A Description of Clinical and Microbiological Findings by Focusing on Risk Factors and Pitfalls.
Fatemeh Karimi, Farzaneh Ashrafi, Azadeh Moghaddas, Ali Derakhshandeh.
J Res Pharm Pract, 2018 Sep 14; 7(3). PMID: 30211240    Free PMC article.
Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar.
Lee S Schwartzberg, Lincy S Lal, +4 authors, Stephanie Korrer.
Clinicoecon Outcomes Res, 2018 Sep 15; 10. PMID: 30214262    Free PMC article.
Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review.
Ricardo Fernandes, Sasha Mazzarello, +10 authors, Mark Clemons.
J Glob Oncol, 2018 Sep 23; 4. PMID: 30241156    Free PMC article.
Systematic Review.
Home administration of filgrastim (Nivestim™) in primary prophylaxis of chemotherapy-induced febrile neutropenia.
Burkhard Otremba, Carsten Hielscher, Volker Petersen, Christian Petrik.
Patient Prefer Adherence, 2018 Nov 10; 12. PMID: 30410313    Free PMC article.
Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study).
Henri Roché, Jean-Christophe Eymard, +6 authors, Alain Toledano.
BMC Cancer, 2018 Nov 18; 18(1). PMID: 30445935    Free PMC article.
Filgrastim prophylaxis in elderly cancer patients in the real-life setting: a French multicenter observational study, the TULIP study.
Kamel Laribi, Delphine Badinand, +5 authors, Rafik Diab.
Support Care Cancer, 2019 Mar 16; 27(11). PMID: 30874925    Free PMC article.
Predictors of chemotherapy-induced severe anemia in cancer patients receiving chemotherapy.
Abolfazl Razzaghdoust, Bahram Mofid, Parvin Peyghambarlou.
Support Care Cancer, 2019 Apr 18; 28(1). PMID: 30993448
Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma.
Shuling Li, Jiannong Liu, +4 authors, David B Chandler.
Support Care Cancer, 2019 Apr 18; 28(1). PMID: 30993450
Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim.
Pere Gascon, Andriy Krendyukov, +2 authors, Matti Aapro.
BioDrugs, 2019 Aug 24; 33(6). PMID: 31440986    Free PMC article.
Mecapegfilgrastim in Chemotherapy-Induced Neutropenia: A Profile of Its Use in China.
Zaina T Al-Salama, Susan J Keam.
Clin Drug Investig, 2019 Sep 07; 39(10). PMID: 31489570
In Vivo Administration of Recombinant Human Granulocyte Colony-Stimulating Factor Increases the Immune Effectiveness of Dendritic Cell-Based Cancer Vaccination.
Shigetaka Shimodaira, Ryu Yanagisawa, +9 authors, Haruo Sugiyama.
Vaccines (Basel), 2019 Sep 25; 7(3). PMID: 31546936    Free PMC article.
Hematopoietic Growth Factors in the Management of Anemia and Febrile Neutropenia.
Hartmut Link.
Breast Care (Basel), 2019 Dec 05; 14(2). PMID: 31798380    Free PMC article.
Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: A phase II study.
Takeshi Ishikawa, Tomoyo Yasuda, +12 authors, Yoshito Itoh.
Cancer Sci, 2019 Oct 28; 110(12). PMID: 31646714    Free PMC article.
The prophylactic effects of long-acting granulocyte colony-stimulating factor for febrile neutropenia in newly diagnosed patients with epithelial ovarian cancer: a randomised controlled study.
Lei Li, Shuiqing Ma, +3 authors, Jinghe Lang.
BMJ Support Palliat Care, 2019 Aug 31; 9(4). PMID: 31467066    Free PMC article.
Risk assessment of febrile neutropenia and evaluation of G-CSF use in patients with cancer: a real-life study.
Elif Aras, Aygin Bayraktar-Ekincioglu, Saadettin Kilickap.
Support Care Cancer, 2019 May 28; 28(2). PMID: 31127438
Effects of Exercise on Chemotherapy Completion and Hospitalization Rates: The OptiTrain Breast Cancer Trial.
Sara Mijwel, Kate A Bolam, +3 authors, Helene Rundqvist.
Oncologist, 2019 Aug 09; 25(1). PMID: 31391297    Free PMC article.
Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2).
Masahiro Yokoyama, Yoshiharu Kusano, +7 authors, Kiyohiko Hatake.
Support Care Cancer, 2019 May 17; 28(2). PMID: 31093770    Free PMC article.
Network Pharmacology-Based Investigation of the System-Level Molecular Mechanisms of the Hematopoietic Activity of Samul-Tang, a Traditional Korean Herbal Formula.
Ho-Sung Lee, In-Hee Lee, Sang-In Park, Dae-Yeon Lee.
Evid Based Complement Alternat Med, 2020 Feb 28; 2020. PMID: 32104198    Free PMC article.
Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma.
Gregory S Calip, Kellyn M Moran, +7 authors, Brian C-H Chiu.
Cancer, 2018 Dec 15; 125(7). PMID: 30548485    Free PMC article.
Prospective Evaluation of Multinational Association of Supportive Care in Cancer Risk Index Score for Gynecologic Oncology Patients With Febrile Neutropenia.
Camille C Gunderson, Britt K Erickson, +4 authors, Kathleen N Moore.
Am J Clin Oncol, 2018 Dec 18; 42(2). PMID: 30557164    Free PMC article.
Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice.
Marie-Rose B S Crombag, Aurelia H M de Vries Schultink, +5 authors, Alwin D R Huitema.
Drugs Aging, 2019 Feb 09; 36(4). PMID: 30734241
Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.
Brian Chen, Sumimasa Nagai, +21 authors, Charles L Bennett.
Oncologist, 2019 Mar 08; 24(4). PMID: 30842244    Free PMC article.
Granulocyte Colony-Stimulating Factor Treatment During Radiotherapy Is Associated With Survival Benefit in Patients With Lung Cancer.
Rui Du, Pingping Hu, +4 authors, Jiandong Zhang.
Technol Cancer Res Treat, 2018 Jan 01; 17. PMID: 31122176    Free PMC article.
Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies.
Ari Brekkan, Luis Lopez-Lazaro, +3 authors, Mats O Karlsson.
AAPS J, 2019 Jul 10; 21(5). PMID: 31286293    Free PMC article.
Paralogs of Common Carp Granulocyte Colony-Stimulating Factor (G-CSF) Have Different Functions Regarding Development, Trafficking and Activation of Neutrophils.
Fumihiko Katakura, Kohei Nishiya, +5 authors, Tadaaki Moritomo.
Front Immunol, 2019 Mar 07; 10. PMID: 30837998    Free PMC article.
Expression and one step intein-mediated purification of biologically active human G-CSF in Escherichia coli.
Setareh Sima, Fatemeh Shafiee, Ali Jahanian-Najafabadi.
Mol Biol Rep, 2020 Apr 01; 47(4). PMID: 32227252
Trends in the use of primary prophylactic colony-stimulating factors and neutropenia-related hospitalization in elderly cancer patients receiving myelosuppressive chemotherapy in the USA: 1995-2015.
Shuling Li, Jiannong Liu, +4 authors, David Chandler.
Support Care Cancer, 2019 Oct 19; 28(6). PMID: 31624920
Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta® in healthy subjects: A randomized, double-blind trial.
Chris Wynne, Christian Schwabe, +6 authors, Michael Stahl.
Pharmacol Res Perspect, 2020 Apr 26; 8(2). PMID: 32333641    Free PMC article.
Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure.
Paul Cornes, Pere Gascon, Arnold G Vulto, Matti Aapro.
BioDrugs, 2020 Apr 02; 34(3). PMID: 32232676    Free PMC article.
Preoperative Nutritional Status Contributes to the Development of Neutropenia Event in Patients With Gastric Cancer Receiving CAPEOX Adjuvant Chemotherapy.
Ai Tang Xiao, Yi Xin Tong, +2 authors, Sheng Zhang.
Front Oncol, 2020 May 20; 10. PMID: 32426291    Free PMC article.
Personalized cancer supportive care in COVID-19 era.
G H Lyman, N M Kuderer.
Ann Oncol, 2020 May 15; 31(7). PMID: 32405154    Free PMC article.
Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrospective Study.
Kentaro Yamao, Mamoru Takenaka, +13 authors, Masatoshi Kudo.
Intern Med, 2019 Apr 19; 58(14). PMID: 30996164    Free PMC article.
Is PEGylated G-CSF superior to G-CSF in patients with breast cancer receiving chemotherapy? A systematic review and meta-analysis.
Xiang Li, Huan Zheng, +4 authors, Juan Xu.
Support Care Cancer, 2020 Jul 06; 28(11). PMID: 32621264    Free PMC article.
Systematic Review.
Prediction of Survival Benefit of Filgrastim in Adult and Pediatric Patients With Acute Radiation Syndrome.
John Harrold, Per Olsson Gisleskog, +4 authors, Murad Melhem.
Clin Transl Sci, 2020 Mar 01; 13(4). PMID: 32112517    Free PMC article.
Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy.
Prasad L Gawade, Shuling Li, +4 authors, Brian D Bradbury.
Support Care Cancer, 2020 Jan 11; 28(9). PMID: 31919669    Free PMC article.
Supportive care during treatment for breast cancer: resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement.
Fatima Cardoso, Nuran Bese, +13 authors, Benjamin O Anderson.
Breast, 2013 Sep 05; 22(5). PMID: 24001709    Free PMC article.
Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim.
Ka-Won Kang, Byung-Hyun Lee, +7 authors, Byung Soo Kim.
Cancer Med, 2020 Jul 08; 9(17). PMID: 32633471    Free PMC article.
Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey.
Rolando Innocenti, Luigi Rigacci, +9 authors, Alberto Bosi.
J Blood Med, 2019 Jan 16; 10. PMID: 30643475    Free PMC article.
Nintedanib in advanced NSCLC: management of adverse events.
Liesbeth Lemmens.
Lung Cancer Manag, 2016 Apr 01; 5(1). PMID: 30643547    Free PMC article.
Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: A systematic review and meta-analysis.
Bo Li, Lian Chen, +3 authors, Wen-Xiong Zhang.
World J Clin Cases, 2019 Mar 14; 7(5). PMID: 30863759    Free PMC article.
Prescribing patterns from medical chart abstraction of patients administered lipegfilgrastim: a pilot study in Europe.
Sigal Kaplan, Nicole Lang, +3 authors, Emanuele Borroni.
J Drug Assess, 2019 May 21; 8(1). PMID: 31105989    Free PMC article.
Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network.
Concetta Conticello, Alessandra Romano, +25 authors, Francesco Di Raimondo.
J Clin Med, 2019 Jun 30; 8(6). PMID: 31248142    Free PMC article.
Development and Validation of a Risk Score for Febrile Neutropenia After Chemotherapy in Patients With Cancer: The FENCE Score.
Theis Aagaard, Ashley Roen, +7 authors, Marie Helleberg.
JNCI Cancer Spectr, 2019 Jul 31; 2(4). PMID: 31360873    Free PMC article.
Pegfilgrastim-induced fatigue and leukocytosis improved following dose reduction in a young patient with breast cancer: A case report.
Haruko Takuwa, Wakako Tsuji, +2 authors, Fumiaki Yotsumoto.
Mol Clin Oncol, 2019 Sep 03; 11(4). PMID: 31475065    Free PMC article.
Machine learning improves the prediction of febrile neutropenia in Korean inpatients undergoing chemotherapy for breast cancer.
Bum-Joo Cho, Kyoung Min Kim, Sanchir-Erdene Bilegsaikhan, Yong Joon Suh.
Sci Rep, 2020 Sep 11; 10(1). PMID: 32908182    Free PMC article.
Detection and Control of Biofilm Formation by Staphylococcus aureus from Febrile Neutropenic Patient.
Ahmed Hazem El-Nagdy, Gamal M Abdel-Fattah, Ziad Emarah.
Infect Drug Resist, 2020 Sep 29; 13. PMID: 32982324    Free PMC article.
Inflammatory Blood Markers as Prognostic and Predictive Factors in Early Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
Ileana Corbeau, Simon Thezenas, +3 authors, Severine Guiu.
Cancers (Basel), 2020 Sep 24; 12(9). PMID: 32962003    Free PMC article.
Clinical Impact of Primary Prophylactic Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel-Doxorubicin-Cyclophosphamide Chemotherapy.
Ye Won Jeon, Seung Taek Lim, +2 authors, Young Jin Suh.
J Breast Cancer, 2020 Nov 07; 23(5). PMID: 33154827    Free PMC article.
Dealing with pre-existing chronic neutropenia in cancer patients-considerations and consequences in the clinical praxis.
Anna-Birgitte Thinggaard, Gabor Liposits, Niels Fristrup.
Ecancermedicalscience, 2020 Nov 20; 14. PMID: 33209122    Free PMC article.
Neutropenic sepsis: a potentially life-threatening complication of chemotherapy.
Amy Ford, Ernie Marshall.
Clin Med (Lond), 2014 Oct 11; 14(5). PMID: 25301919    Free PMC article.
Irinotecan-induced neutropenia is reduced by oral alkalization drugs: analysis using retrospective chart reviews and the spontaneous reporting database.
Hirofumi Hamano, Marin Mitsui, +16 authors, Keisuke Ishizawa.
Support Care Cancer, 2018 Aug 01; 27(3). PMID: 30062585
Real-world use of granulocyte colony-stimulating factor in ambulatory breast cancer patients: a cross-sectional study.
Florence Van Ryckeghem, Chloë Haverbeke, +5 authors, Simon Van Belle.
Support Care Cancer, 2018 Aug 14; 27(3). PMID: 30099601
Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" (< 24 h), "per-guidelines" (24-72 h), and "late" (> 72 h): findings from the MONITOR-GCSF study.
Heinz Ludwig, Pere Gascón, +6 authors, Ivo Abraham.
Support Care Cancer, 2018 Oct 22; 27(6). PMID: 30343410
SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018).
A Carmona-Bayonas, P Jimenez-Fonseca, +7 authors, F Ayala de la Peña.
Clin Transl Oncol, 2018 Nov 25; 21(1). PMID: 30470991    Free PMC article.
The timing of docetaxel initiation in metastatic castrate-sensitive prostate cancer and the rate of chemotherapy-induced toxicity.
Igal Kushnir, Kim Koczka, +4 authors, M Neil Reaume.
Med Oncol, 2019 Jan 23; 36(2). PMID: 30666463
Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
Zsuzsanna Kahan, Daniela Grecea, +6 authors, Ildiko Aradi.
BMC Cancer, 2019 Feb 08; 19(1). PMID: 30727980    Free PMC article.
Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice.
Wolfgang Janni, Andreas Schneeweiss, +14 authors, Johannes Ettl.
Geburtshilfe Frauenheilkd, 2019 Mar 19; 79(3). PMID: 30880825    Free PMC article.
Effects of short-term fasting on cancer treatment.
Stefanie de Groot, Hanno Pijl, Jacobus J M van der Hoeven, Judith R Kroep.
J Exp Clin Cancer Res, 2019 May 23; 38(1). PMID: 31113478    Free PMC article.
Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study.
Derek Weycker, Robin Doroff, +6 authors, Gary H Lyman.
BMC Cancer, 2019 Aug 11; 19(1). PMID: 31399079    Free PMC article.
Impact of granulocyte colony-stimulating factor on FOLFIRINOX-induced neutropenia prevention: A population pharmacokinetic/pharmacodynamic approach.
Pauline Macaire, Justine Paris, +3 authors, Antonin Schmitt.
Br J Clin Pharmacol, 2020 May 10; 86(12). PMID: 32386071    Free PMC article.
Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art.
Massimo Martino, Annalisa Paviglianiti, +2 authors, Claudio Cerchione.
Front Oncol, 2020 Dec 03; 10. PMID: 33262948    Free PMC article.
Current management of chemotherapy-induced neutropenia in adults: key points and new challenges: Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association Committee of Clinical Chemotherapy, China Anti-Cancer Association.
Yi Ba, Yuankai Shi, +38 authors, Chenfei Zhou.
Cancer Biol Med, 2020 Dec 11; 17(4). PMID: 33299642    Free PMC article.
The impact of granulocyte colony-stimulating factor use in patients with metastatic breast cancer treated with palliative chemotherapy: a single-institution retrospective review.
Luay Mousa, Julie A Stephens, +9 authors, Robert Wesolowski.
Support Care Cancer, 2020 Mar 19; 28(11). PMID: 32185556
Predicting Chemotherapy-Induced Neutropenia and Granulocyte Colony-Stimulating Factor Response Using Model-Based In Vitro to Clinical Translation.
Wenbo Chen, Britton Boras, +3 authors, David Z D'Argenio.
AAPS J, 2020 Nov 07; 22(6). PMID: 33156437    Free PMC article.
Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC).
Mark Clemons, Sasha Mazzarello, +12 authors, Dean Fergusson.
Support Care Cancer, 2018 Aug 14; 27(4). PMID: 30099602
Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.
Jean Paul Salmon, Martin Smakal, +5 authors, James O'Kelly.
Support Care Cancer, 2018 Sep 28; 27(4). PMID: 30259136
G-CSF guideline adherence in Germany, an update with a retrospective and representative sample survey.
Hartmut Link, Markus Kerkmann, +2 authors, Working Groups Supportive Care (ASORS now AGSMO) and Medical Oncology (AIO) within the German Cancer Society (DKG).
Support Care Cancer, 2018 Oct 31; 27(4). PMID: 30374765    Free PMC article.
Supportive care in patients with cancer during the COVID-19 pandemic.
M Aapro, G H Lyman, +7 authors, N M Kuderer.
ESMO Open, 2021 Jan 10; 6(1). PMID: 33421735    Free PMC article.
Prospective cohort study of febrile neutropenia in breast cancer patients administered with neoadjuvant and adjuvant chemotherapies: CSPOR-BC FN study.
Takashi Ishikawa, Kentaro Sakamaki, +14 authors, for Comprehensive Support Project for Oncological Research of Breast Cancer.
Breast, 2021 Feb 26; 56. PMID: 33631458    Free PMC article.
Meta-analysis: combination of meropenem vs ceftazidime and amikacin for empirical treatment of cancer patients with febrile neutropenia.
Ying Wang, Zhichao Du, +2 authors, Zhitang Yang.
Medicine (Baltimore), 2021 Mar 06; 100(8). PMID: 33663117    Free PMC article.
Systematic Review.
Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer.
Pietro Lapidari, Arnauld Gbenou, +17 authors, Antonio Di Meglio.
Breast, 2021 Mar 13; 57. PMID: 33711699    Free PMC article.
Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey.
Uros Markovic, Alessandra Romano, +16 authors, Concetta Conticello.
Front Oncol, 2021 Mar 26; 11. PMID: 33763359    Free PMC article.
Chemotherapy induced neutropenia and febrile neutropenia among breast cancer patients in a tertiary hospital in Nigeria.
Omolola Salako, Kehinde Sharafadeen Okunade, +2 authors, Oluwasegun Joshua Afolaranmi.
Ecancermedicalscience, 2021 Mar 30; 15. PMID: 33777181    Free PMC article.
Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis).
Masahiro Yokoyama, Yoshiharu Kusano, +5 authors, Yasuhito Terui.
BMC Cancer, 2021 Apr 08; 21(1). PMID: 33823836    Free PMC article.
Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study.
Hartmut Link, G Illerhaus, +9 authors, A Buchner.
Support Care Cancer, 2020 Sep 19; 29(5). PMID: 32944800    Free PMC article.
G-CSF in tumors: Aggressiveness, tumor microenvironment and immune cell regulation.
Ioannis Karagiannidis, Eralda Salataj, Erika Said Abu Egal, Ellen J Beswick.
Cytokine, 2021 Mar 08; 142. PMID: 33677228    Free PMC article.
Safety and efficacy of administering reduced doses of pegylated recombinant human granulocyte-colony stimulating factors in patients treated with cisplatin and etoposide for small cell carcinoma: A retrospective study.
Chang Liu, Ying Hao, +3 authors, Diansheng Zhong.
Thorac Cancer, 2021 Feb 17; 12(8). PMID: 33590721    Free PMC article.
Optimizing Dose-Adjusted EPOCH Chemotherapy with Long-Acting Granulocyte Colony-Stimulating Factor During the COVID-19 Epidemic.
Chong Wei, Yan Zhang, Wei Wang, Wei Zhang.
Cancer Manag Res, 2021 Apr 22; 13. PMID: 33880064    Free PMC article.
Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patients.
Michael Metz, Dieter Semsek, +14 authors, Karin Potthoff.
Support Care Cancer, 2021 May 07;. PMID: 33956213
A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
Mark Clemons, Dean Fergusson, +18 authors, REThinking Clinical Trials (REaCT) investigators.
Breast, 2021 Apr 27; 58. PMID: 33901921    Free PMC article.
Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma.
Claudio Cerchione, Davide Nappi, Giovanni Martinelli.
Support Care Cancer, 2021 May 16;. PMID: 33990881
A Multicenter Study of Docetaxel at a Dose of 100 mg/m2 in Japanese Patients with Advanced or Recurrent Breast Cancer.
Taizo Hirata, Shinji Ozaki, +9 authors, Hiroyoshi Doihara.
Intern Med, 2020 Nov 17; 60(8). PMID: 33191320    Free PMC article.
A Community Hospital-Based Study: A Prespecified Neutrophil Count with Adjuvant mFOLFOX6 Associated with Increased Delays, Increased G-CSF Use, and Reduced Dose Intensity.
James A Chiarotto, George Dranitsaris.
Cancer Manag Res, 2021 May 28; 13. PMID: 34040446    Free PMC article.
Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety.
Reshma Mahtani, Jeffrey Crawford, +3 authors, Prasad L Gawade.
BMC Cancer, 2021 May 29; 21(1). PMID: 34044798    Free PMC article.
Pooled Analysis on the Effectiveness and Safety of Lipegfilgrastim in Patients With Urological Malignancies in the Real-World Setting.
Axel S Merseburger, Götz Geiges, +2 authors, Petra Pichler.
Front Oncol, 2021 Jun 15; 11. PMID: 34123810    Free PMC article.
Systematic Review.
Improving Outcomes of Chemotherapy: Established and Novel Options for Myeloprotection in the COVID-19 Era.
Gary H Lyman, Nicole M Kuderer, Matti Aapro.
Front Oncol, 2021 Jul 27; 11. PMID: 34307165    Free PMC article.